In analyzing the forecast data for the re-import of insulin to France from 2024 to 2028, a steady annual growth is observed. The value of re-imports rises gradually from 7.01 thousand USD in 2024 to 7.24 thousand USD in 2028. While the forecast for the prior year, 2023, isn't explicitly provided, this consistent increase suggests a positive year-on-year escalation in demand or value. The year-on-year growth between each projected year hovers around 0.8-0.9%, indicating stable upward momentum. The compound annual growth rate (CAGR) over this five-year period remains modest, reflecting predictable and stable market conditions.
Future trends to monitor include potential shifts in global insulin supply chains, which could be influenced by changes in international trade policies, biotechnology advancements, or evolving health regulations within France. Monitoring these factors will be crucial for accurately projecting adjustments in import activity.
